Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Shenzhen Stock Exchange 002693.SZ

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Market Capitalization on January 14, 2025: USD 912.67 M

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Market Capitalization is USD 912.67 M on January 14, 2025, a 107.64% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. 52-week high Market Capitalization is USD 2.23 B on October 29, 2024, which is 144.24% above the current Market Capitalization.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. 52-week low Market Capitalization is USD 251.99 M on February 07, 2024, which is -72.39% below the current Market Capitalization.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. average Market Capitalization for the last 52 weeks is USD 647.46 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Shenzhen Stock Exchange: 002693.SZ

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

CEO	Mr. Jianming Li
IPO Date	Aug. 8, 2012
Location	China
Headquarters	No. 16 Xingguo Road
Employees	474
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate for injections, as well as vitamin B6. The company was founded in 2000 and is based in Haikou, the People's Republic of China.

Key trends

Past 5 years